Other than ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy more than enough to tolerate FCR therapy, should be superior candidates with the latter, with the benefit being this treatment method could be finished in six months when ibrutinib has to be taken indefinitely. This selection might be specifically valuable for non-